研究单位：[1]Ruijin Hospital, Shanghai Jiaotong University School of Medicine,Shanghai,Shanghai,China,200025[2]Shandong Cancer Hospital and Institute[3]Sichuan Cancer Hospital & Institute[4]Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center[5]Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, China
The purpose of this trial is to compare the toxicities and efficacy of intensity-modulated proton therapy (IMPT) and intensity-modulated radiation therapy (IMRT) for breast cancer patients indicated for radiotherapy including preoperative radiotherapy, postoperative radiotherapy, or definitive radiotherapy. IMPT or IMRT will be administered to the whole breast, chest wall, and/or regional lymph nodes. A boost dose will be delivered in patients with high-risk area, at the discretion of the radiation oncologist. Eligible breast cancer patients will be followed for at least 5 years to assess acute and late radiation induced toxicities, loco-regional recurrence, overall survival, distant metastasis, and quality of life.
